99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging

Inclusion Criteria:

* Diagnosis of primary and recurrent glioma;
* Sequential injection of 99mTc-1-thio-D-glucose and 18F-FET in the interval of 14 days in each patient;
* Hematological, liver and renal function test results within the following limits:

  * White blood cell count: \> 2.0 x 109/L
  * Hemoglobin: \> 80 g/L
  * Platelets: \> 50.0 x 109/L
  * Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST): =\< 5.0 times Upper Limit of Normal
  * Bilirubin =\< 2.0 times Upper Limit of Normal
  * Serum creatinine: Within Normal Limits
* A negative pregnancy test for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination;
* Subject is capable to undergo the diagnostic investigations to be performed in the study;
* Informed consent.

Exclusion Criteria:

* Second, non-brain malignancy;
* Active current autoimmune disease or history of autoimmune disease;
* Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening);
* Known HIV positive or chronically active hepatitis B or C;
* Administration of other investigational medicinal product within 30 days of screening;
* Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's.